Rice Hall James & Associates’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Rice Hall James & Associates’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-22,628	Closed	-$912K	–	309
2018 Q4	$912K	Buy	22,628 +2,101	+10%	+$108K	0.03%	249
2018 Q3	$1.42M	Sell	20,527 -14,932	-42%	-$1.13M	0.05%	229
2018 Q2	$2.68M	Buy	35,459 +14,452	+69%	+$909K	0.1%	145
2018 Q1	$1.11M	Buy	+21,007	New	+$1.22M	0.04%	238
2017 Q3	–	Sell	-201,904	Closed	-$15.9M	–	301
2017 Q2	$15.9M	Buy	201,904 +71,185	+54%	+$5.82M	0.69%	69
2017 Q1	$10.8M	Buy	+130,719	New	+$9.72M	0.53%	80

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Rice Hall James & Associates's EGRX Position: Q1 2019 in Review

Rice Hall James & Associates sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2019, closing a stake of 22,628 shares — an estimated $912K sold.

Rice Hall James & Associates first reported a position in EGRX in Q1 2017 and held it in 6 quarters. The position peaked at $15.9M in Q2 2017. 182 funds tracked by Wall St. Rank hold EGRX as of Q1 2019.

Rice Hall James & Associates reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
Rice Hall James & Associates sold 22,628 Eagle Pharmaceuticals, Inc. shares in Q1 2019, an estimated $912K.
Rice Hall James & Associates first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2017 and held it in 6 quarters.
Rice Hall James & Associates's Eagle Pharmaceuticals, Inc. position peaked at $15.9M in Q2 2017.
182 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2019.

Based on Rice Hall James & Associates's 13F filing for Q1 2019, filed 1 May 2019.